Gaxos.ai Inc. Raises $3.6 Million in Gross Proceeds from Warrant Exercise Transaction

Roseland, NJ, Aug. 17, 2026 (GLOBE NEWSWIRE) — Gaxos.ai Inc. (NASDAQ: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various high-growth sectors, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 3,007,654 shares of common stock originally issued in December 2024 and September 2024, having exercise prices ranging from $2.33 to $3.32 per share, at a reduced exercise price of $1.20 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statements on Form S-1 (No. 333-292709) and Form S-3 (File No. 333-282739).

Ferrari Enzo Tops Broad Arrow’s Record-Setting $97.4 Million Debut of The Quail Auction

Broad Arrow’s 2026 The Quail Auction, as the official auction partner of The Quail by The Peninsula, A Motorsports Gathering, reached $97.4 million in total sales with an 85 percent sell-through rate | Broad Arrow’s highest grossing Monterey Car Week sale to date topped by 2003 Ferrari Enzo finished in Nero D.S. over Rosso and sold to a millennial collector for $10,675,000 | Innovative new presentation onsite at The Quail Golf Club brings a premium auction experience to The Quail by The Peninsula, A Motorsports Gathering | No less than 8 new world record auction prices set over two days, led by the 2025 Bugatti W16 Mistral at $8,805,000 and the 2011 Bugatti Veyron 16.4 Grand Sport at $3,305,000 | Complete results and information on upcoming auctions available at broadarrowauctions.com

Broad Arrow’s 2026 The Quail Auction, as the official auction partner of The Quail by The Peninsula, A Motorsports Gathering, reached $97.4 million in total sales with an 85 percent sell-through rate | Broad Arrow’s highest grossing Monterey Car Week sale to date topped by 2003 Ferrari Enzo finished in Nero D.S. over Rosso and sold to a millennial collector for $10,675,000 | Innovative new presentation onsite at The Quail Golf Club brings a premium auction experience to The Quail by The Peninsula, A Motorsports Gathering | No less than 8 new world record auction prices set over two days, led by the 2025 Bugatti W16 Mistral at $8,805,000 and the 2011 Bugatti Veyron 16.4 Grand Sport at $3,305,000 | Complete results and information on upcoming auctions available at broadarrowauctions.com

Non-Postoperative Pain Management Market Set for Significant Growth During the Forecast Period (2026–2036), Driven by Novel Non-Opioid Therapies | DelveInsight

The non-postoperative pain management market is witnessing steady growth, driven by the increasing prevalence of acute and chronic pain conditions, rising demand for effective non-surgical pain therapies, and greater emphasis on opioid-sparing treatment strategies. Advances in non-opioid analgesics, targeted therapies, and innovative drug delivery technologies are expanding the treatment landscape. In addition, the expected launch of emerging therapies such as TK-254Rx (esflurbiprofen transdermal) (Teikoku Pharma), RizaFilm (rizatriptan) (Gensco Pharma), ELYXYB (Scilex Holding Company), and others will further propel the market growth.

The non-postoperative pain management market is witnessing steady growth, driven by the increasing prevalence of acute and chronic pain conditions, rising demand for effective non-surgical pain therapies, and greater emphasis on opioid-sparing treatment strategies. Advances in non-opioid analgesics, targeted therapies, and innovative drug delivery technologies are expanding the treatment landscape. In addition, the expected launch of emerging therapies such as TK-254Rx (esflurbiprofen transdermal) (Teikoku Pharma), RizaFilm (rizatriptan) (Gensco Pharma), ELYXYB (Scilex Holding Company), and others will further propel the market growth.

PeptidesCalculator.org Unveils Free Retatrutide Dosage Calculator to Streamline Research Protocols

New York, United States, Aug. 17, 2026 (GLOBE NEWSWIRE) — PeptidesCalculator.org, a leading provider of digital solutions for peptide research, today announced the launch of its new, free-to-use dedicated tool: the retatrutide dosage calculator. Engineered to deliver precision and eliminate manual mathematical errors, the web-based utility simplifies complex reconstitution and dosing math for researchers working with next-generation triple-agonist peptides.

CORRECTION: TDECU Board Elects Lavonne Burke as New Chair

Houston, TX, Aug. 17, 2026 (GLOBE NEWSWIRE) — TDECU has elected attorney and technology executive Lavonne Burke as Chair of its Board of Directors, signaling a continued focus on innovation, governance and long-term growth for the Houston region’s largest credit union. Burke, who joined the TDECU Board in 2023, is the first woman to serve as Board Chair in TDECU’s 71-year history.

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory.

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory.

In National Advertising Division Challenge, Quanovate Tech Voluntarily Discontinues Mira Fertility Monitor and Test Wand Claims

Following a BBB National Programs’ National Advertising Division challenge brought by The Procter & Gamble Company (P&G), Quanovate Tech, Inc. voluntarily discontinued claims for its Mira Fertility Monitor and Test Wands.

Following a BBB National Programs’ National Advertising Division challenge brought by The Procter & Gamble Company (P&G), Quanovate Tech, Inc. voluntarily discontinued claims for its Mira Fertility Monitor and Test Wands.